Strategic Collaboration Strategic partnership with Novo Nordisk to co-develop oral SCD therapies signals a clear channel for BD outreach. Target opportunities include joint grant proposals, co-marketing agreements, and expansion into chronic disease portfolios where Bach1 inhibition could translate to additional indications.

SCD Focus Core emphasis on sickle cell disease as a flagship modality creates a direct sales path to hematology and rare disease teams. Explore opportunities with CROs, patient advocacy groups, and specialty pharmacies to accelerate clinical adoption and access programs.

Early-Stage Advantage Small, venture-funded profile with early-stage development and first-in-class targets offers a doorway for research collaborations, licensing discussions, and pilot programs that can de-risk larger deals for larger pharma partners hungry for innovative mechanisms.

Global Access Promise Commitment to globally accessible therapies suggests value-driven pricing discussions, outcomes-based contracts, and patient access initiatives. Propose BD strategies around tiered pricing, payer engagement, and regional market entry plans.

Digital & Tech Readiness Utilize their tech stack and cloud-enabled operations to propose integrated digital health and data-sharing partnerships, such as real-world evidence deployments, AI-enabled trial optimization, and secure collaboration platforms for co-development with potential partners.